top of page
Pink Sky banner 2.jpeg

Efficacy of EQNMT’s Psychedelic-Assisted Therapy Program

Take a Closer Look

Our therapeutic framework integrates neuroscience with various therapeutic tools from different traditions and can be applied with different psychedelic agents for a wide variety of conditions (trans-diagnostic).

Our efficacy data represents the results of 71 people (N=71) (unless otherwise specified) who participated in EQNMT’s psychedelic-assisted therapy program to date, resulting in a 98% success rate.

We commit to updating our data continually to provide a transparent picture of client outcomes.

Our success rate was determined by calculating the mean (average) scores of the following measures, from pre-retreat to 6 months post-retreat:

Beck Anxiety Scale (BAS)

The lower the score, the less anxious the person feels.

Beck Depression Inventory (BDI)

The lower the score, the less depressed the person feels.

Pre-Post Measure _BAS and BDI.png
Patient Health Questionnaire (PHQ9)

The data represents changes in self-reported depression. The lower the score, the less depressed the person feels.

Yale-Brown OCD Scale
(YBOCS)

The lower the score, the milder the OCD symptoms.

Hamilton Depression Scale
(HAM-D)

The lower the score, the less depressed the person feels.

Pre-Post Measure _PHQ 9_YBOCS_HAM-D.png
World Health Organization Quality of Life Scale (WHOQoLS)

The WHOQoLS has four scales-
 

Phys = Physical
Psych = Psychological
Soc = Social
Env = Environmental

 

The higher the score, the better the quality of life.

Pre-Post Measure _WHOQoLS.png
The data portrayed below represents changes in self-reported substance use.
The graphs represent mean (average) scores of N (number)= 25 participants from pre-retreat to 6 months post-retreat.

N = 5 cocaine
N =12 cannabis
N = 18 alcohol
 
Scoring:

Below 50= Full remission
50-60= Partial remission
60-70= Mild-moderate substance use
Above 70= Clinically significant substance abuse

 
Pre-Post Measure _PAI Alc PAI Drg.png

The initial data indicates promising, enduring outcomes for clients seeking relief from Depression, Anxiety, OCD and Substance Use by participating in EQNMT’s evidence-based psychedelic-assisted therapy programs.

The Science of Psychedelic-Assisted Therapy

Psilocybin therapy, which involves the controlled use of the psychoactive compound psilocybin found in certain mushrooms, has shown promise as an effective treatment for a range of mental health disorders. While research in this area is ongoing, several key neuroscientific mechanisms underlie its potential efficacy:

It's important to note that psilocybin therapy is still in its early stages of research, and its efficacy and safety need further investigation. Moreover, it should only be administered in a controlled, therapeutic setting under the guidance of trained professionals.

 

While it holds potential as a treatment option for certain mental health disorders, it is not a standalone solution and should be considered as part of a broader approach that may include psychotherapy and other interventions.

Multiple published studies showing the safety and efficacy of psychedelic-assisted therapy.

 

EQNMT combines the therapeutic approaches from all of these studies to overcome the limitation of each as a standalone treatment.

bottom of page